Search

Bacillus calmette-guerin substrain russian BCG-I live antigen

thought to work by stimulating a local immune and inflammatory response in the bladder. … [L32729,A232264] The live Russian BCG-I substrain of BCG was granted a notice of compliance with conditions by Health Canada in February 2021.

Quinine

An alkaloid derived from the bark of the cinchona tree. … It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633.

LJP 1082

The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I. … Patients with high levels of anticardiolipin antibodies (ACA) have an increased risk of stroke, heart attack, deep vein thrombosis, and recurrent fetal loss.

Lesinurad

Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target … In August 2017, a combination oral therapy consisting of lesinurad and [DB00437] was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with

Riltozinameran

The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. … [L43917] Riltozinameran is an mRNA vaccine encoding the S glycoprotein of SARS-CoV-2 Omicron variant lineage BA.1.

Poa pratensis pollen

Poa pratensis pollen is mainly used in allergenic testing.

ING-1

It is an attractive target for immunotherapy. … ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most

Technetium Tc-99m etidronate

Piperaquine

Piperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China [A31550]. … Eurartesim was first authorized for market by the European Medicines Agency in October 2011.

Isocarboxazid

[A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders. … [T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.